Keyphrases
1H nuclear Magnetic Resonance (1H NMR)
18%
4-fluorophenyl
47%
Activity Relationship
23%
Acyl
23%
ADMET
70%
ADMET Properties
23%
Anti-breast Cancer
23%
Anti-breast Cancer Agents
23%
Anticancer Activity
90%
Anticancer Drug Candidates
40%
Anticancer Drugs
68%
Benzoyl
28%
Benzoyloxy
47%
Benzoylurea
32%
Breast Cancer Cells
23%
Butyrate
23%
Cancer Drugs
23%
Checkpoint Kinase 1 (CHK1)
23%
Chloride
31%
Clinical Chemistry
23%
Compound Modified
23%
COX-2 Inhibitors
23%
Cytotoxic Activity
76%
Derivative Synthesis
23%
Docking Activity
23%
HeLa Cell Line
29%
HeLa Cells
28%
Human Epidermal Growth Factor Receptor 2 (HER2)
23%
Hydroxyurea
41%
IC50
29%
In Silico
31%
In Silico Study
28%
In Silico Tests
26%
In Vitro Cytotoxicity
31%
In Vitro Study
23%
Molecular Docking
75%
Molecular Docking Studies
23%
MTT Assay
28%
MTT Method
26%
N-allylthiourea
23%
Pinostrobin
47%
Property-based
23%
Propionate
23%
Quantitative Structure
23%
Selectivity Index
23%
Synthesized Compounds
42%
T47D
23%
Thiourea
38%
Thiourea Derivatives
39%
Urea
70%
Pharmacology, Toxicology and Pharmaceutical Science
Absorption Distribution Metabolism Excretion
16%
Absorption-Distribution-Metabolism-Excretion Toxicity
47%
Ammonium Thiocyanate
7%
Anthranilic Acid
7%
Anticancer Drug
19%
Anticarcinogen
90%
Benzoyl Chloride
5%
Binding Site
15%
Biological Activity
15%
Bond Energy
13%
Breast Cancer
47%
Butyrate
23%
Carbon 13
21%
Checkpoint Kinase 1
23%
COX-2 Inhibitor
23%
Cytotoxic Agent
5%
Cytotoxicity
100%
Cytotoxicity Assay
7%
Drug Development
9%
Drug Discovery
7%
Electrospray Ionization
7%
Epidermal Growth Factor Receptor
15%
Epidermal Growth Factor Receptor 2
23%
Heart Disease
7%
Hepatotoxicity
5%
Hydroxycarbamide
52%
IC50
50%
Malignant Neoplasm
82%
Nonanoic Acid
9%
Pharmacokinetics
17%
Phenylthiocarbamide
12%
Propionic Acid
23%
Protein Binding
7%
Protein P53
5%
QSAR Study
23%
Quantitative Structure-Activity Relationship
23%
Quinazolinone Derivative
7%
Receptor
12%
Ribonucleotide Reductase
5%
Tetrahydrofuran
5%
Thiourea
45%
Thiourea Derivative
39%
Urea Derivative
5%
Virtual Screening
7%